LEAS Stock Overview
ANEW MEDICAL, INC. focuses on developing biologic medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
ANEW MEDICAL, INC. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.0098 |
| 52 Week Low | US$0.0001 |
| Beta | 0.27 |
| 1 Month Change | -97.20% |
| 3 Month Change | -85.19% |
| 1 Year Change | -50.00% |
| 3 Year Change | -87.50% |
| 5 Year Change | -87.50% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LEAS | US Diversified Financial | US Market | |
|---|---|---|---|
| 7D | -92.6% | 1.9% | 1.2% |
| 1Y | -50.0% | 24.3% | 24.9% |
Price Volatility
| LEAS volatility | |
|---|---|
| LEAS Average Weekly Movement | 49.5% |
| Diversified Financial Industry Average Movement | 5.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LEAS's share price has been volatile over the past 3 months.
Volatility Over Time: LEAS's weekly volatility has decreased from 62% to 41% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 1 | Joe Sinkule | www.anewmeds.com |
ANEW MEDICAL, INC. focuses on developing biologic medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. The company is based in Omaha, Nebraska.
ANEW MEDICAL, INC. Fundamentals Summary
| LEAS fundamental statistics | |
|---|---|
| Market cap | US$208.97k |
| Earnings (TTM) | -US$684.87k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs LEAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEAS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$684.87k |
| Earnings | -US$684.87k |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00065 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 193.0% |
How did LEAS perform over the long term?
See historical performance and comparison